What is HC Wainwright’s Estimate for LifeMD Q3 Earnings?

LifeMD, Inc. (NASDAQ:LFMD) – Research analysts at HC Wainwright lowered their Q3 2026 earnings per share (EPS) estimates for shares of LifeMD in a note issued to investors on Friday, August 7th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of ($0.15) for the quarter, down from their prior forecast of ($0.05). HC Wainwright has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for LifeMD’s current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for LifeMD’s Q4 2026 earnings at $0.06 EPS, FY2026 earnings at ($0.46) EPS, Q1 2027 earnings at ($0.07) EPS, Q2 2027 earnings at ($0.13) EPS, Q3 2027 earnings at ($0.09) EPS and FY2027 earnings at ($0.12) EPS.

LifeMD (NASDAQ:LFMD) last announced its earnings results on Wednesday, August 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01). The business had revenue of $47.28 million during the quarter, compared to analyst estimates of $49.16 million. LifeMD had a net margin of 0.10% and a negative return on equity of 168.23%.

A number of other research analysts also recently commented on the stock. Mizuho set a $7.00 price objective on shares of LifeMD in a research note on Thursday, August 6th. UBS Group reissued a “buy” rating on shares of LifeMD in a report on Wednesday, May 27th. Zacks Research downgraded shares of LifeMD from a “hold” rating to a “strong sell” rating in a research report on Friday, July 17th. KeyCorp set a $5.00 target price on shares of LifeMD and gave the company an “overweight” rating in a research note on Friday, August 7th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of LifeMD in a research report on Tuesday, August 4th. Eight equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, LifeMD currently has an average rating of “Moderate Buy” and an average price target of $7.57.

LifeMD Trading Down 1.5%

LFMD stock opened at $3.27 on Monday. The firm has a 50 day simple moving average of $4.19 and a 200-day simple moving average of $3.96. The company has a market capitalization of $157.61 million, a P/E ratio of -65.39 and a beta of 2.02. LifeMD has a twelve month low of $2.56 and a twelve month high of $7.32.

Institutional Investors Weigh In On LifeMD

A number of institutional investors have recently modified their holdings of LFMD. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in LifeMD by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,647 shares of the company’s stock worth $270,000 after acquiring an additional 2,235 shares during the last quarter. Creative Planning acquired a new position in LifeMD in the second quarter valued at approximately $272,000. JPMorgan Chase & Co. grew its holdings in shares of LifeMD by 581.2% during the second quarter. JPMorgan Chase & Co. now owns 412,571 shares of the company’s stock valued at $5,619,000 after purchasing an additional 352,004 shares during the last quarter. Legal & General Group Plc grew its holdings in shares of LifeMD by 187.4% during the second quarter. Legal & General Group Plc now owns 10,144 shares of the company’s stock valued at $138,000 after purchasing an additional 6,614 shares during the last quarter. Finally, Rhumbline Advisers raised its position in shares of LifeMD by 8.7% during the 2nd quarter. Rhumbline Advisers now owns 53,589 shares of the company’s stock worth $730,000 after purchasing an additional 4,281 shares during the period. Institutional investors own 35.52% of the company’s stock.

LifeMD Company Profile

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.